Vulvar and Vaginal Atrophy
2 original drugsVulvar and Vaginal Atrophy has 2 FDA-approved novel treatments, led by MILLICENT across 1 drug target. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.
Vulvar and Vaginal Atrophy Market Leaders
Companies with the most FDA-approved novel Vulvar and Vaginal Atrophy drugs.
Vulvar and Vaginal Atrophy Treatments by Mechanism
Top 1 mechanisms across 1 industry trials with a known mechanism of action.
MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.
Vulvar and Vaginal Atrophy Clinical Pipeline by Phase
11 industry-sponsored trials across 11 sponsors
Precision Medicine Biomarkers
All biomarkers →Biomarkers used for patient selection in Vulvar and Vaginal Atrophy
Novel Vulvar and Vaginal Atrophy Drugs by Company (New molecular entities)
2 companies have an FDA-approved novel drug for Vulvar and Vaginal Atrophy.
Reformulations (10 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
Vulvar and Vaginal Atrophy Drug Targets
Molecular targets of approved and investigational Vulvar and Vaginal Atrophy drugs — 1 target tracked.
Generic Drugs (4 ANDA approved) Click to expand
Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs